Atara Biotherapeutics, Inc.
ATRA· Nasdaq
Released Nov 9, 2020, after the close
10-Q filed Nov 9, 2020, 40 days after period end · 0001564590-20-052503
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Net Income | -$74.35M | -$71.90M | -$58.36M | -$31.10M |
| EPS Diluted | -$0.92 | -$1.31 | -$1.29 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR